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A B S T R A C T   
Tumors of Lynch syndrome (LS) patients display high levels of microsatellite instability (MSI), which results from 
complete loss of DNA mismatch repair (MMR), in line with Knudson’s two-hit hypothesis. Why some organs, in 
particular those of the gastrointestinal (GI) tract, are prone to tumorigenesis in LS remains unknown. We hy-
pothesized that MMR is haploinsufficient in certain tissues, compromising microsatellite stability in a tissue- 
specific manner before tumorigenesis. Using mouse genetics, we tested how levels of MLH1, a central MMR 
protein, affect age- and tissue-specific microsatellite stability in vivo and whether elevated MSI is detectable prior 
to loss of MMR function and to neoplastic growth. 
To assess putative tissue-specific MMR haploinsufficiency, we determined relevant molecular phenotypes 
(MSI, Mlh1 promoter methylation status, MLH1 protein and RNA levels) in jejuna of Mlh1+/− mice and compared 
them to those in spleen, as well as to MMR-proficient and -deficient controls (Mlh1+/+ and Mlh1− /− mice). While 
spleen MLH1 levels of Mlh1+/− mice were, as expected, approximately 50 % compared to wildtype mice, MLH1 
levels in jejunum varied substantially between individual Mlh1+/− mice and moreover, decreased with age. 
Mlh1+/− mice with soma-wide Mlh1 promoter methylation often displayed severe MLH1 depletion in jejunum. 
Reduced (but still detectable) MLH1 levels correlated with elevated MSI in Mlh1+/− jejunum. MSI in jejunum 
increased with age, while in spleens of the same mice, MLH1 levels and microsatellites remained stable. Thus, 
MLH1 expression levels are particularly labile in intestine of Mlh1+/− mice, giving rise to tissue-specific MSI long 
before neoplasia. A similar mechanism likely also operates also in the human GI epithelium and could explain the 
wide range in age-of-onset of LS-associated tumorigenesis.   
1. Introduction 
Lynch syndrome (LS) is an autosomal-dominant cancer syndrome 
characterized by a high risk of developing colorectal cancer (CRC), 
endometrial cancer and various other cancers. LS accounts for 1–5 % of 
all CRC cases; individuals with LS have >80 % lifetime risk of devel-
oping CRC and are diagnosed with CRC at an average age of 44 years. LS 
patients carry germline heterozygous mutations in one of the DNA 
mismatch repair (MMR) genes, typically MLH1 and MSH2 [1–3]. MMR is 
required for the repair of single base pair mismatches and small 
insertion-deletion (indel) mutations which arise from strand-slippages 
during DNA replication [4,5]. Microsatellites (short DNA tandem re-
peats), because of their repetitive nature, are highly prone to such 
replication errors [4,6], which if left unrepaired leads to indel mutations 
in MMR-deficient cells, a phenotype known as microsatellite instability 
(MSI) [4,7]. High-level MSI is a molecular hallmark of LS patients’ tu-
mors and indicates defective MMR [8,9]. The conventional notion of 
MSI in LS-associated CRC is that it follows Knudson’s two-hit hypothesis 
[10]: both MMR alleles must be defective in order to trigger MSI. In this 
model, the first hit is inherited as a germline defect in an MMR gene, and 
the remaining functional MMR allele is lost (i.e. second hit) by somatic 
mutations, epigenetic inactivation or loss of heterozygosity (LOH), 
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leading to a complete loss of MMR function (MMR deficiency) that ini-
tiates the MSI mutator phenotype, subsequently instigating tumorigen-
esis [11–13]. 
Certain observations, however, suggest that MMR genes may be 
haploinsufficient, i.e., that loss of function of just one allele may lead to 
compromised genome integrity. Firstly, LS patients show low-level MSI 
in peripheral blood leukocytes and in normal colon mucosa [14–16]. 
Additionally, cell-free extracts from Mlh1+/− mouse embryonic fibro-
blasts show decreased MMR activity [7], low MMR levels reduce MMR 
efficiency in non-neoplastic human cell lines [17,18], and Mlh1 hemi-
zygosity increases indel mutations in cancer cell lines [19]. Given these 
hints of MMR haploinsufficiency, we hypothesized that reduced MMR 
protein levels may provoke microsatellite instability in certain tissues, 
such as the highly proliferating (and tumor-prone) intestinal epithelium 
in mice, already prior to the “second hit”. 
The MSI mutator phenotype and MMR deficiency associated tumor 
spectrum has been extensively characterized in a constitutional Mlh1 
knock-out mouse model (Mlh1− /− mice), and these animals have a high 
incidence of MMR-deficient MSI-high GI tumors [7,20–22]. Unlike in 
humans, GI tumorigenesis in MMR-deficient mice preferentially affects 
the small intestine (in particular, jejunum and ileum) and not the colon 
[20], thus in MMR mouse models, small intestine is used to study the 
cellular and molecular phenotypes related to GI tumorigenesis [21, 
23–25]. Here, we used Mlh1 heterozygous (Mlh1+/− ) mice [7,22] as 
model of LS to test tissue-specific MMR haploinsufficiency. As in LS, 
Mlh1+/− mice have early-onset of GI tract tumors, and increased mor-
tality [21]. 
To test the effect of age and Mlh1 heterozygosity on MSI in jejunum, 
we used sensitive single-molecule PCR to quantify MSI in normal 
jejunum of 4- and 12-month-old Mlh1+/− mice, and compared MSI rates 
with those from jejunum of age-matched Mlh1+/+ mice. To study the 
tissue-specificity of MSI, we compared the jejunum MSI data with 
(recently published [26] and additional) spleen MSI data from the same 
mice. In addition, we assayed MSI in Mlh1− /− jejuna at both time points, 
and in an intestinal tumor from a 12-month-old Mlh1− /− mouse. We also 
measured Mlh1 mRNA and MLH1 protein expression levels in different 
organs of Mlh1+/− mice, focusing on the comparison between the small 
intestine (highly proliferative [27] and tumor-prone) and spleen (less 
proliferating [28] and no MMR-dependent tumors reported) to assess 
the correlation of MLH1 expression with MSI. Finally, we tested loss of 
heterozygosity (LOH) and promoter methylation at Mlh1 as possible 
explanations for the tissue-specific reduction in MLH1 expression. 
2. Methods 
2.1. Mice and genotyping 
Mlh1 mice (B6.129- Mlh1tm1Rak, strain 01XA2, National Institutes of 
Health, Mouse Repository, NCI-Frederick) [7] were bred and maintained 
according to national and institutional guidelines (Animal Experiment 
Board in Finland and Laboratory Animal Centre of the University of 
Helsinki). Mlh1 genotyping was performed using ear pieces as previ-
ously described [26]. In total, 57 mice (38 males and 19 females) were 
used in this study. DNA, RNA and protein (western blot) analyses were 
performed in same set of mice (see Supplementary Table 2). For this, a 
total of 35 mice were used, and the numbers of Mlh1+/+, Mlh1+/− and 
Mlh1− /− mice were: 5, 12 and 3 at 4-month and 3, 10 and 2 at 12-month 
time points, respectively. In addition, ten 1-month-old mice were used 
for RNA analysis: 3 Mlh1+/+, 5 Mlh1+/− and 2 Mlh1− /− mice. A different 
set of twelve mice, all 4 months old, were used for immunohistochem-
istry (IHC), as follows: 4 Mlh1+/+, 6 Mlh1+/− and 2 Mlh1− /− mice. The 
number of mice for each experiment, along with genotype and age, is 
indicated in the respective figures in the results section. A subset of mice 
(18 male mice: 3 Mlh1+/+ and 6 Mlh1+/− mice each for 4- and 12-month 
time point) used in this study were the same mice for which MSI and 
methylation status of Mlh1 promoter in sperm and spleen was assayed in 
our recent publication [26]. 
2.2. Tissue collection for DNA, RNA and protein analysis 
The small intestine was flushed with cold phosphate-buffered saline 
(PBS), cut open longitudinally and visually inspected for visible tumors. 
A 3cm long piece of jejunum was cut approximately 15 cm from the 
pyloric sphincter. This tissue piece, henceforth referred to simply as 
“jejunum”, was approximately the center of the small intestine. Jejunum 
was inspected for any macroscopic tumor-like outgrowth under a ste-
reoscope, and only normal-looking tissue pieces were used for the ex-
periments. The jejunum was snap-frozen and stored at − 80 ◦C. Other 
tissues and Mlh1− /− intestinal tumors were also collected, snap-frozen 
and stored at − 80 ◦C. Frozen tissues were used for subsequent DNA, 
RNA and protein analysis. 
2.3. DNA extraction and single-molecule MSI analysis by PCR 
MSI was assayed at the single-DNA molecule level, as described 
previously [26]. Briefly, DNA was extracted using AllPrep DNA/R-
NA/Protein Mini Kit (Qiagen, Hilden, Germany) according to manu-
facturer’s instructions. Approximately 5 mg of tissue was used for DNA 
extraction. The extracted DNA was quantified using a Qubit fluorometer 
(Thermo Fisher Scientific, Waltham, MA) and diluted to 30 pg/μl con-
centration in 5 mM Tris-HCl (pH 7.5) supplemented with 5 ng/μl carrier 
herring sperm (Thermo Fisher Scientific). The MSI assay was performed 
using single-molecule PCR (SM-PCR) [26,29]. Three microsatellites, two 
mononucleotide repeats A27 and A33 [30], and a dinucleotide repeat 
D14Mit15 [7] were assayed for MSI. To ensure that individual PCRs are 
seeded with a single amplifiable DNA molecule, we estimated the 
number of amplifiable molecules by using a dilution series (30 pg, 6 pg, 
4.5 pg and 0.6 pg of input DNA) for each DNA sample analyzed, similar 
to previous reports [26,31]. We determined the DNA concentration that 
yielded a PCR product in approximately 50 % of reactions. By Poisson 
approximation, this PCR success rate equates to approximately one 
amplifiable molecule per positive reaction [26,29,31,32]. SM-PCR 
methodology (including PCR primers and cycling conditions) was 
described in detail previously [26]. DNA fragments were analyzed by 
capillary electrophoresis, using ABI3730xl DNA Analyzer (Thermo 
Fisher Scientific). Between 116 and 205 amplifiable DNA molecules per 
tissue per mouse were assayed for each microsatellite locus. Data was 
analyzed using Fragman R package [33]. The mutation rates reported 
here are likely a conservative estimate, because stringent criteria were 
used for true microsatellite signal calling and for mutant calling, as 
described previously [26]. In brief, as a true microsatellite signal should 
have stutter peaks, signals without stutter peaks were considered arti-
facts. An allele was scored as mutant only when the highest peak and the 
stutter peaks shifted as one unit; shift of the highest peak only was not 
considered as mutant allele. In case of co-occurrence of a wild-type allele 
and a mutant allele in a single PCR, the reaction was scored as wild-type 
allele. For each microsatellite, MSI was scored separately for insertions 
and deletions in terms of number of single repeat-unit shifts observed.  
MSI rate = total number of single repeat unit shifts observed / total DNA 
molecules analyzed                                                                                
Hence, MSI rate equals 1 if every DNA molecule analyzed in the 
sample has a single repeat unit shift. If some DNA molecules have larger 
(>single repeat unit) shifts, then MSI rate can be >1. 
2.4. RNA extraction and RNA expression analysis 
RNA was extracted using AllPrep DNA/RNA/Protein Mini Kit (Qia-
gen) according to manufacturer’s instructions. Extracted RNA was 
measured using NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA). 500 ng of extracted RNA was reverse- 
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transcribed using SuperScript VILO cDNA Synthesis Kit (Invitrogen). 
Quantitative PCR (qPCR) was performed in CFX96 Touch Real-Time 
PCR Detection System (Bio-Rad) using SsoAdvance Universal SYBR 
Green Supermix system (Bio-Rad, Hercules, CA). PCR conditions were as 
follows: 30 s at 95 ◦C, 40 cycles of 10 s at 95 ◦C, 30 s at 60 ◦C, and 5 s at 
72 ◦C. The following primers were used for qPCR: for Mlh1, forward 
primer 5′ GGGAGGACTCTGATGTGGAA 3′ and reverse primer 5′
AGAGCTTGGTCTGGTGCTGT 3′ (amplicon size: 216 bp), and for beta- 
actin, forward primer 5′ AGACTTCGAGCAGGAGATGG 3′ and reverse 
primer 5′ AGGTCTTTACGGATGTCAACG 3′ (amplicon size: 210 bp). 
Gene expression data of Mlh1 was normalized to beta-actin. Data was 
analyzed using Bio-Rad CFX Maestro (version 1.1). 
2.5. Western blot analysis 
Frozen tissue pieces were thawed on ice, mechanically homogenized 
in RIPA buffer supplemented with protease inhibitor cocktail (Roche, 
Basel, Switzerland), incubated for 30 min on ice and centrifuged at 
14,000 rpm for 10 min at 4 ◦C. The supernatant was collected and stored 
at − 80 ◦C until further use. Total protein concentration was measured 
using Pierce™ BCA™ protein assay kit (Thermo Fisher Scientific), 30 μg 
of total protein extract was used for western blotting. The denatured 
protein was run in 4–20 % gradient Mini-Protean TGX gels (Bio-Rad) 
and transferred to 0.2 μm nitrocellulose membrane using Trans-Blot 
Transfer Pack (Bio-Rad). To confirm complete protein transfer, mem-
branes were stained with Ponceau solution for 5 min at room tempera-
ture. Membranes were blocked with 5% milk in PBS supplemented with 
1 μl/mL Tween-20 (Thermo Fisher Scientific) for 1 h at room tempera-
ture, and incubated overnight at 4 ◦C with primary antibodies against 
MLH1 (1:1000, Abcam, Cambridge, UK, catalog no. ab92312), and Beta- 
actin (1:5000, Sigma, Missouri, USA, catalog no. A5441), followed the 
next day by infrared IRDye 800CW (1:5000, Li-COR, Nebraska, USA, 
catalog no. 926-32211) and IRDye 680RD (1:5000, Li-COR, catalog no. 
926-68070) secondary antibody incubation for 1 h at room temperature. 
LI-COR Odyssey FC system (LI-COR) was used to scan the membranes 
and LI-COR Image Studio lite (version 5.2) was used for image analysis. 
MLH1 protein signal intensities were normalized to beta-actin signal 
intensity. 
2.6. Immunohistochemistry (IHC) and histological image analysis 
The small intestine was flushed with cold 1xPBS, fixed overnight in 
4% paraformaldehyde, cut open longitudinally, embedded into paraffin 
blocks as a “Swiss roll” [34], and sectioned at 4 μm thickness. 
Heat-induced antigen retrieval was performed for 20 min using 10 mM 
citrate buffer (pH 6). MLH1 was detected using anti-MLH1 antibody 
(1:1500, Abcam, catalog no. ab92312), and visualized using Bright-
Vision Poly HRP goat anti-rabbit IgG (ImmunoLogic, Duiven, The 
Netherlands, catalog no. DPVR55HRP). Sections were counterstained 
with hematoxylin-eosin. Slides were scanned using 3DHistech Pano-
ramic 250 FLASH II digital slide scanner (3DHistech, Budapest, 
Hungary) at 20X magnification, and images were visualized using 
CaseViewer (version 2.2). For each mouse, MLH1 protein levels were 
quantified for five randomly selected sites in the jejunum, each site 
consisting of approximately ten villus-crypt units, altogether approxi-
mately 50 villus-crypt units per jejunum. Quantification was performed 
using IHC Profiler plugin in ImageJ [35]. 
2.7. Mlh1 LOH analysis 
LOH was tested using restriction fragment length polymorphism 
(RFLP) assay on two large PCR products that covered approximately 20 
% of the Mlh1 gene in total, and were located at the far 5′ and 3′ ends of 
the Mlh1 gene. These regions spanned exons 1 and 19, respectively, and 
we refer to them as RFLP_exon 1 and RFLP_exon 19 from here on 
(Fig. 3A). 50 ng of DNA was seeded into each PCR which was performed 
using Phusion High-Fidelity DNA Polymerase system (Thermo Fisher 
Scientific). The following primers were used: for RFLP_exon 1, forward 
primer 5′ GGCTTACCTGCCAGCACAACC 3′ and reverse primer 5′
CCGTGTGCATAATGGGAAACC 3′, and for RFLP_exon 19, forward 
primer 5′ GAGTATGCCAGTAGCTGGGAG 3′ and reverse primer 5′
CAGTTCAAAGATCGGGCAAG 3′. PCR conditions were as follows: 30 s at 
98 ◦C, 35 cycles of 10 s at 98 ◦C, 20 s at 70 ◦C and 120 s at 72 ◦C, fol-
lowed by 10 min at 72 ◦C. PCR product sizes of RFLP_exon 1 and 
RFLP_exon 19 were 4 kb and 5.7 kb, respectively. 200 ng of PCR product 
of RFLP_exon1 and RFLP_exon 19 were digested with PstI (New England 
Biolabs) and VspI (Thermo Fisher Scientific) restriction enzymes, 
respectively, according to manufacturer’s instruction. Mlh1+/+ and 
Mlh1− /− jejunum DNA was used as normal and knock-out allele controls, 
respectively. Digested PCR products were analyzed by gel electropho-
resis on an ethidium bromide stained 1.5 % agarose gel. DNA samples 
were considered to have undergone LOH if the samples displayed the 
same banding pattern as the PCR seeded with Mlh1− /− DNA. 
2.8. Mlh1 promoter methylation analysis by methylation-specific PCR 
(MSP) 
Methylation status of the Mlh1 promoter was tested by MSP, as 
described previously [26]. Briefly, 200 ng of genomic DNA was 
bisulfite-converted, and 2 μl of bisulfite-converted DNA was used for 
MSP. Two different PCRs were set up in parallel, one with a primer pair 
specific to methylated CpG sites at the Mlh1 promoter (forward primer 5′
GGTGTACGAAGTTATTTTTATTTTAGTC 3′ and reverse primer 5′
ACCCAACGATACCTAATAATAAAACC 3′) (Zymo Research, Irvine, CA, 
catalog no. D2012), and another with a primer pair specific to unme-
thylated CpG at the same sites (forward primer 5′ GGTGTATGAAGT-
TATTTTTATTTTAGTT 3′ and reverse primer 5′
ACCCAACAATACCTAATAATAAAACC 3′). PCR conditions were as fol-
lows: 10 min at 95 ◦C, 40 cycles of 30 s at 95 ◦C, 45 s at 58 ◦C and 60 s at 
72 ◦C, followed by 7 min at 72 ◦C. PCRs were performed in triplicate, 
and run on a 1.5 % agarose gel stained with ethidium bromide and 
visualized by UV light. A sample was scored as Mlh1 promoter methyl-
ated if all MSP triplicates (with primers specific to methylated CpG sites) 
displayed a PCR product. Faint PCR products were also scored as Mlh1 
promoter methylated, as long as they were seen across triplicates. 
2.9. Statistical analysis 
Statistical testing was done using an unpaired t-test, and linear 
regression fitting was tested using F-test. Two-tailed P-values < 0.05 
were considered statistically significant. 
3. Results 
3.1. Normal jejunum of Mlh1+/− mice displays MSI 
We investigated the effect of Mlh1 heterozygosity on Mlh1 expression 
levels and on microsatellite stability in the intestine, in both younger 
and older mice (Fig. 1A). Spleen was used as a control for tissue- 
specificity. MSI was quantified by highly sensitive SM-PCR on three 
microsatellite loci (two mononucleotide repeats and one dinucleotide 
repeat, Fig. 1B) in 4- and 12-month-old Mlh1+/− mice. Mlh1+/+ and 
Mlh1− /− tissues were used as MMR-proficient and MMR-deficient con-
trols, respectively, and MSI was also assessed in an intestinal tumor from 
a 12-month-old Mlh1− /− mouse. 
Compared to age-matched Mlh1+/+ jejuna, in Mlh1+/− jejuna de-
letions at mononucleotide repeats were elevated (observed deletions 
were predominantly single repeat unit, i.e., 1 bp shifts) (Fig. 1C,D), 
while the dinucleotide repeat D14Mt15 was stable (Supplementary 
Fig. 1). At 4 and 12 months, Mlh1+/− jejuna showed 2-fold (p = 0.007) 
and 5-fold (p = 0.001) increase in mononucleotide tract deletions 
compared to Mlh1+/+ jejuna, respectively. Compared to Mlh1− /− jejuna, 
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on the other hand, they were reduced 9-fold (p = 0.0001) and 13-fold (p 
= 0.0001), respectively (Fig. 1D). 12-month Mlh1+/− jejuna showed a 
1.5-fold increase (p = 0.006) in deletions compared to 4-month Mlh1+/−
jejuna (Fig. 1D). In contrast to Mlh1+/− jejunum, deletion mutant alleles 
in Mlh1− /− jejunum displayed bigger size shifts at both time points, and 
were more frequent at all three microsatellites (Fig. 1C–D and Sup-
plementary Fig. 1A–B). When comparing deletions at mononucleotide 
repeats, Mlh1− /− jejunum samples had 21-fold (p = 0.0001) and 60-fold 
(p = 0.0001) higher deletion rates compared to age-matched Mlh1+/+
jejuna (Fig. 1D). For comparison, the Mlh1− /− intestinal tumor showed 
90- and 20-fold increase in deletions compared to 12-month Mlh1+/+
and Mlh1+/− jejuna, respectively (Fig. 1D). 
Unlike what was observed for deletions, at the 4-month time point 
Mlh1+/+ jejuna showed an insertional burden at mononucleotide tracts, 
in particular at A33. Insertions further increased with age in Mlh1+/+
jejuna (for A33 1.7-fold, p = 0.01, and for A27 1.5-fold (p = n.s), see 
Supplementary Fig. 2). In 4-month-old jejuna, average insertion rates 
at mononucleotide repeats were similar across all genotypes (Mlh1+/+, 
Mlh1+/− , Mlh1− /− ). However, 4-month Mlh1+/− jejuna showed a wide 
range of inter-individual variation in insertions at A33 (range: 1.7 %– 
11.9 %). In 12-month-old jejuna, mononucleotide repeat insertions 
decreased with decreasing Mlh1 gene dosage (Supplementary Fig. 2). 
Insertions in Mlh1+/− and Mlh1− /− jejuna were 1.8-fold to 2.9-fold lower 
when compared to Mlh1+/+ (Supplementary Fig. 2). The decrease in 
insertions in Mlh1− /− jejuna compared Mlh1+/− jejuna was not signifi-
cant (Supplementary Fig. 2). Irrespective of genotype or age, insertions 
in jejunum were almost exclusively single repeat unit in size (1 bp and 2 
bp for mono- and dinucleotide repeats, respectively) (Fig. 1C and Sup-
plementary Fig. 1A). 
In general, indels in dinucleotide repeat D14Mit15 were infrequent 
in Mlh1+/+ and Mlh1+/− jejuna at both time points (Supplementary 
Fig. 1). Mutant alleles at D14Mit15 were predominantly deletions in 
Mlh1+/+and Mlh1+/− jejuna, and their frequency was similar between 
the two genotypes. Mlh1− /− jejuna showed MSI at D14Mit15 at both 
Fig. 1. Normal jejunum of Mlh1+/− mice displays MSI at mononucleotide repeats at 4- and 12-month time points. (A) Workflow of the study. In mice of the 
indicated genotypes, we tested Mlh1 expression (both at mRNA and protein level) and MSI. From DNA samples, we also tested LOH at Mlh1 gene and assayed Mlh1 
promoter methylation status. (B) Representative capillary electropherograms of single-molecule PCR (SM-PCR) based MSI assay for A27, A33 and D14Mit15 
microsatellites. Top and bottom panels show electropherograms scored as wildtype and single repeat unit deletion mutant alleles, respectively. The highest peaks 
(indicated by shading in each electropherogram) were scored; lower peaks are stutter peaks, a typical feature of microsatellite markers. (C) Heat map of allele 
frequency (%) detected at mononucleotide repeats in jejunum of mice of the indicated genotypes, as well as in an intestinal tumor from Mlh1− /− mouse. (D) MSI rates 
for deletions in jejunum. Similar data for insertions is shown in Supplementary Fig. 2. Statistical testing was performed using unpaired t-test. Purple arrow indicates 
the outlier Mlh1+/− mouse. This mouse was excluded from the heat map in (B) and is shown separately in Supplementary Fig. 3. 
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time points (Supplementary Fig. 1B). Compared to mononucleotide 
repeats, deletions at the dinucleotide repeat D14Mit15 were 4.5-fold and 
4-fold lower in 4- and 12-month old Mlh1− /− jejuna, respectively 
(Fig. 1D and Supplementary Fig. 1B). 
MSI was also assessed in spleen DNA of the same mice (previously 
published in [26] and additional new data in Supplementary Table 1), 
enabling comparisons of jejunum MSI to spleen MSI overall, as well as 
within each mouse. In contrast to Mlh1+/− jejuna, there was no sub-
stantial increase in mononucleotide repeat deletions in Mlh1+/− spleens 
compared to age-matched Mlh1+/+, nor did MSI increase with age in 
either genotype (Supplementary Table 1). As in Mlh1+/+ jejunum, 
Mlh1+/+ spleens also showed insertional bias, however, unlike in the 
jejunum, insertion rates in Mlh1+/+ and Mlh1+/− spleens were 
comparable (Supplementary Table 1). Mlh1− /− spleens showed 
elevated MSI; deletions predominated and increased with age (Sup-
plementary Table 1). As in jejunum, the dinucleotide repeat D14Mit15 
was stable in Mlh1+/+ and Mlh1+/− spleens at both time points, and 
Mlh1− /− spleens showed elevated MSI (Supplementary Table 1). 
Inter-individual variation in deletions at mononucleotide repeats 
was evident in Mlh1+/− jejuna in both age groups (Fig. 1D). Moreover, 
one 4-month-old Mlh1+/− mouse showed substantially elevated de-
letions in jejunum (6- and 4-fold higher compared to other age-matched 
Mlh1+/− mice at mononucleotide markers and at D14Mit15, respec-
tively), indicated by an arrow in Fig. 1D and Supplementary Fig. 1B. 
With Grubbs’ test, this Mlh1+/− mouse was classified as an outlier (p <
0.05). In this mouse, deletions in jejunum consisted of predominantly 
Fig. 2. Jejuna of Mlh1+/− mice show tissue-specific sporadic depletion in MLH1 expression at 4 and 12 months of age. (A) Mlh1 mRNA expression analysis. 
Arrow indicates data point for the outlier Mlh1+/− mouse with high deletion rates at mononucleotide repeats. Red dotted line across each boxplot indicates the 
average value. Dashed black line across the chart marks 50 % expression level. (B) and (C) MLH1 protein levels analysis. (B) Representative image of western blot. 
Empty lanes in western blot do not necessarily mean absence of MLH1 but possibly MLH1 protein levels below detectable range of our western blot assay (Sup-
plementary Fig. 7). Boxplot shows MLH1 protein expression analysis for the western blots. The red-dotted line across each boxplot represents the average value. The 
dashed-horizontal line across the chart indicates 50 % MLH1 protein expression. Histogram shows MLH1 protein expression in jejunum of individual mice; genotypes 
are indicated as black, grey and white. Based on MLH1 protein expression levels, the Mlh1+/− jejuna fall into two distinct sub-groups: one with close-to-expected 
MLH1 expression (MLH1normal, pink box) and the other with very low MLH1 expression (MLH1low, blue box). Dashed line across the chart marks 50 % MLH1 of 
wild-type protein expression. (C) Representative IHC images of jejunum. Middle two IHC images shows a side-by-side comparison of villus-crypt units scored as (a) 
positive and (b) low positive by IHC profiler. 
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one and two repeat shifts (Supplementary Fig. 3). We previously re-
ported 4.9 % deletions at mononucleotide repeats in spleen DNA of this 
mouse (which was 2-fold higher than in other Mlh1+/− spleens), while 
D14Mit15 was stable [26]. 
3.2. Mlh1+/− mice show sporadic decrease in MLH1 expression levels in 
jejunum 
To assess whether the inter-individual variation in deletion fre-
quencies in Mlh1+/− jejuna can be explained by Mlh1 expression levels, 
we quantified Mlh1 mRNA and MLH1 protein levels using qPCR and 
western blot, respectively. Mlh1+/− spleens, which were microsatellite- 
stable (Supplementary table 1), were used as control tissue. To further 
examine tissue-specific differences in Mlh1 expression, we analyzed 
Mlh1 mRNA expression in brain, kidney and liver using qPCR. We also 
assessed variation in MLH1 expression by immunohistochemistry (IHC) 
in jejunum of 4-month-old mice. 
In Mlh1+/− jejuna, average Mlh1 expression (both at mRNA and 
protein levels) was less than the expected ~50 % of Mlh1+/+ jejuna 
(Fig. 2A and B). Further, average expression was lower in the older age 
group, implying age-dependent MLH1 depletion. In addition, expression 
levels varied between individual Mlh1+/− mice; mice in the 4-month-old 
group showed more inter-individual variation than those in the 12- 
month-old group. At 4 months, Mlh1+/− jejuna showed on average 26 
% Mlh1 mRNA (range: 8 %–46 %) and 21 % (range: 0.4 %–53 %) MLH1 
protein expression compared to Mlh1+/+ levels, and at 12 months the 
average Mlh1 mRNA and MLH1 protein expression decreased to 16 % 
(range: 9 %–26 %) and 17 % (range: 0.2 %–32 %), respectively (Fig. 2A 
and B). These age-specific decreases in Mlh1 mRNA and MLH1 protein 
were not statistically significant, however. Based on MLH1 protein 
expression levels in jejunum, Mlh1+/− mice clustered into two sub- 
groups. One sub-group expressed close-to-expected, that is, approxi-
mately 50 % of wildtype MLH1 protein levels (range: 18 %–53 % and 19 
%–32 % at the 4- and 12-month time points, respectively), while the 
other expressed much less MLH1 protein (< 4% at both time points). 
Henceforth, we refer to these sub-groups of Mlh1+/− mice as MLH1normal 
and MLH1low, respectively (histogram in Fig. 2B). 
To investigate whether younger mice show similar aberration in 
Mlh1 expression levels, we analyzed Mlh1 mRNA expression levels also 
at 1-month time point. As the older cohorts, 1- month Mlh1+/− jejuna 
also showed less-than-expected- and variable Mlh1 mRNA expression 
levels (average: 30 %, range: 21 %–37 %) (Supplementary Fig. 4). 12- 
month-old Mlh1+/− mice showed a significant decrease in Mlh1 mRNA 
levels in jejunum (p = 0.0283) when compared to 1-month old Mlh1+/−
mice (Supplementary Fig. 4). 
Irrespective of age, we observed approximately the expected 50 % 
Mlh1 mRNA and MLH1 protein levels in all the Mlh1+/− spleens 
(Fig. 2A,B and Supplementary Fig. 4). Jejunum of the outlier Mlh1+/−
mouse showed only 8% Mlh1 mRNA expression (Fig. 2A) and no 
detectable MLH1 protein (Fig. 2B), while its spleen had the expected 
levels of Mlh1 mRNA and MLH1 protein (Fig. 2A and B). 
We also assayed Mlh1 mRNA expression in brain, kidney and liver of 
two 4-month-old Mlh1+/− mice that expressed below age-average Mlh1 
mRNA levels in their jejunum; Mlh1 mRNA expression in these tissues 
were close to the expected ~50 % (60 %, 56 % and 56 %, respectively) 
(Supplementary Fig. 5). 
Substantial inter-individual variation in MLH1 protein expression in 
Mlh1+/− jejuna (n = 6) was also detectable by IHC. Based on the staining 
intensity, jejuna of half of the Mlh1+/− mice were scored as MLH1- 
positive and the other half was scored as MLH1 low-positive by IHC 
profiler (Fig. 2C). Upon further analyzing intestinal crypts and villi 
separately, in MLH1 low-positive jejuna we observed decreased MLH1 
staining intensity in both; moreover, all MLH1-negative cells were 
located in the villi rather than in the crypt (Supplementary Fig. 6). 
3.3. Tissue-specific depletion of MLH1 in jejunum of Mlh1+/− mice 
associates with constitutive Mlh1 promoter methylation and not with loss 
of heterozygosity (LOH) at Mlh1 
The variable MLH1 protein levels in jejunum of Mlh1+/− mice 
ranging from approximately expected 50 % of Mlh1+/+ to no expression 
(Fig. 2B) prompted us to investigate possible causes of this sporadic 
MLH1 depletion. To distinguish between genetic (LOH) and epigenetic 
(methylation of the Mlh1 promoter) mechanisms, we performed re-
striction fragment length polymorphism (RFLP) analysis and 
methylation-specific PCR (MSP) assay, respectively (Fig. 3A). 
LOH in Mlh1+/− jejuna was tested using RFLP at the 5′ and 3′ ends of 
Mlh1 gene (regions spanning exon 1 and exon 19, respectively) (Fig. 3A). 
Out of 22 Mlh1+/− jejunum DNA samples assayed (n = 12 and 10 for 4- 
and 12-month time point, respectively), LOH was only observed in the 4- 
month-old outlier Mlh1+/− mouse (Fig. 3B and Supplementary Fig. 8). 
Both RFLP_exon 1 and RFLP_exon 19 regions in this mouse had under-
gone LOH (Fig. 3B). 
Mlh1 promoter methylation status was assayed using MSP (per-
formed in triplicate, see Supplementary Fig. 9). For any given sample, 
the Mlh1 promoter was scored as methylated only if PCR products were 
detected in all MSP triplicates, performed with primers specific to 
methylated CpG sites. Mlh1 promoter methylation in jejunum was 
common (detected in 9/12 and 7/10 Mlh1+/− mice at 4 and 12 months, 
respectively, Fig. 3C). Irrespective of age, all Mlh1+/− jejuna with very 
low MLH1 protein expression (<4% of age-matched Mlh1+/+ jejuna) 
displayed Mlh1 promoter methylation (histogram in Fig. 3C). Addi-
tionally, three 4-month- and four 12-month-old Mlh1+/− mice with in-
termediate MLH1 protein expression (18–28 % of wildtype level) 
showed Mlh1 promoter methylation (see Fig. 3C, bottom panel). One 4- 
month-old Mlh1+/− mouse with 53 % MLH1 expression showed faint but 
consistent across-triplicates MSP signal (marked by grey “M” in Fig. 3C). 
Three Mlh1+/− mice in each age group did not show Mlh1 promoter 
methylation; MLH1 expression in these mice ranged from 21 % to 53 % 
(Fig. 3C). 
We then tested Mlh1 promoter methylation status in additional tis-
sues. For spleen and sperm of six Mlh1+/− males each both age groups, 
Mlh1 promoter methylation status was reported earlier [26] and here, 
we expand the cohort by testing Mlh1 promoter methylation status in 
spleen of Mlh1+/− females (n = 6 and n = 4 for 4-month and 12-month 
time point, respectively, Supplementary Fig. 10). Irrespective of age, 
all Mlh1+/− mice with Mlh1 promoter methylation in jejunum also 
showed Mlh1 promoter methylation in their spleen, and in the case of 
males, also in sperm. We further selected three Mlh1+/− mice positive for 
jejunum and spleen Mlh1 promoter methylation to test for Mlh1 pro-
moter methylation status in brain, and Mlh1 promoter methylation was 
seen there as well (Supplementary Fig. 10). None of the Mlh1+/+ tis-
sues assayed showed Mlh1 promoter methylation while all Mlh1− /−
tissues showed Mlh1 promoter methylation (Fig. 3 and Supplementary 
Fig. 10). Unlike Mlh1+/− jejunum, where Mlh1 promoter methylation 
status associated with reduced Mlh1 expression (Fig. 3C), all Mlh1+/−
spleen samples – irrelevant the Mlh1 promoter methylation status – had 
the expected, approximately 50 % of wildtype Mlh1 expression, as 
quantified both at the RNA and protein level (Fig. 2A-B). 
3.4. MSI correlates with reduced MLH1 protein level in jejunum of 
Mlh1+/− mice 
Within each Mlh1+/− jejunum sample, we then explored the rela-
tionship between deletion frequency at mononucleotide repeats and 
MLH1 protein expression. At the 4-month time point, MLH1normal and 
MLH1low Mlh1+/− jejuna displayed 2-fold (p = 0.002) and 3-fold (p =
0.001) more deletions compared to Mlh1+/+ (Fig. 4). At the 12-month 
time point, the increase in MLH1normal and MLH1low Mlh1+/− jejuna 
was 4-fold (p < 0.0001) and 7-fold (P = 0.0009), respectively (Fig. 4). In 
jejunum of the Mlh1+/− outlier mouse (indicated by arrow in Fig. 4), 
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Fig. 3. Mlh1 promoter methylation, but not Mlh1 LOH, is frequent in Mlh1+/− jejuna. (A) Schematic of MSP and LOH assay design. MSP and LOH assays were 
performed in twelve 4-month-old and ten 12-month-old Mlh1+/− mice. (B) Representative gel image of PCR-RFLP. Arrow indicates the outlier Mlh1+/− mouse. See 
Supplementary Fig. 8 for PCR-RFLP gel images on remaining Mlh1+/− jejunum samples. (C) Representative gel image of MSP assay. Histogram below the gel image 
shows MLH1 protein expression (as % of wildtype average, data from Fig. 2B) for each Mlh1+/− jejunum sample. Mlh1 promoter methylation per each sample is 
indicated by “M” (i.e. MSP-positive jejunum samples). “▴” indicates those samples in which MSP signal was detected in only one or two of the MSP triplicates (see 
Supplementary Fig. 9) and were scored as MSP-negative. “M” in grey font indicates faint MSP signal. “*” indicates Mlh1+/− mice for which MSP was also performed 
in brain. See Supplementary Fig. 9 for gel images of replicate MSPs for jejuna, ref. [26] and Supplementary Fig. 10 for MSP data for spleen, and Supplementary 
Fig. 10 for brain. Sample order in C is the same as in [26] (males) and as in Supplementary Fig. 10 (females). Arrow indicates the outlier Mlh1+/− mouse. 
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there was no detectable MLH1 protein, and deletions were 14-fold more 
frequent compared to age-matched Mlh1+/+ jejuna. Linear regression 
analysis between deletions and jejunum MLH1 expression grouped the 
two Mlh1+/− sub-groups into two distinct clusters, and deletions and 
MLH1 protein expression showed an inverse correlation at both time 
points (R2 = 0.51 and 0.41, and P = 0.0005 and 0.006 for 4- and 12- 
month time point, respectively) (Supplementary Fig. 11). Irre-
spective of age, all Mlh1+/− spleens showed the expected approximately 
50 % MLH1 protein level, and no increase in deletions compared to 
Mlh1+/+ spleens. The exception was the spleen sample of the outlier 
Mlh1+/− mouse which had 2-fold more deletions compared to age- 
matched Mlh1+/− spleens, despite having normal protein expression 
level (Supplementary Fig. 12). 
4. Discussion 
Mlh1 mice [7,22] are a powerful model to comprehensively study 
MSI, and to dissect molecular mechanisms contributing to the MSI 
phenotype. In line with previous studies [30,36], we observed mono-
nucleotide repeats to be more unstable than dinucleotide repeats. The 
key to detecting subtle cellular phenotypes with pre-malignant poten-
tial, such as low-level MSI, is to employ sufficiently sensitive molecular 
read-outs. SM-PCR, when applied to unstable microsatellite loci, can 
detect MSI levels as low as 1%, whereas standard PCR has a detection 
limit of 20–25 % [37]. Analyzing less unstable microsatellite markers by 
conventional PCR may result even in failure to detect MSI in Mlh1+/−
tumors [38]. 
Overall, MSI in Mlh1+/− mice was higher compared to Mlh1+/+ mice, 
and increased with age. Further, jejunum-specific MSI varied substan-
tially between Mlh1+/− mice of the same age group, and tracked with 
depleted MLH1 protein levels. These observations are in line with those 
reported for LS patients who showed inter-individual variation in MSI 
(including the age at which it was detected) in peripheral blood leuko-
cyte DNA [15]. In addition, already in very young (1-month-old) 
Mlh1+/− mice jejunum-specific inter-individual variation in Mlh1 mRNA 
levels, and lower-than-expected Mlh1 mRNA levels were observed, 
suggesting that the cellular changes (including MSI) may occur even 
earlier. 
LS-associated colorectal cancers are MMR-deficient and show high- 
level MSI, which led to the notion that disruptive mutations in both 
allelic MMR gene copies are required to instigate the MSI phenotype [9, 
11]. However, recent evidence of LS-associated adenomas retaining 
(some) MMR function suggests that the second hit may arise later in the 
multi-step tumorigenesis than previously appreciated [39], making the 
idea of pre-tumorigenic MMR haploinsufficiency more plausible. We 
demonstrate here that MSI is present in normal jejuna of Mlh1+/− mice 
with expected MLH1 levels (approximately 50 % of wildtype), but not in 
other tissues assayed, indicating tissue-specific MMR haploinsufficiency. 
Surprisingly, all Mlh1+/− mice harboring Mlh1 promoter methylation 
in jejunum also showed Mlh1 promoter methylation in other tissues 
Fig. 4. Deletions at mononucleotide repeats increase with decreasing MLH1 levels in jejunum of Mlh1þ/¡mice. Comparison (unpaired t-test) of deletion rates 
between all genotypes, as well as the two Mlh1+/− sub-groups. Arrow indicates the outlier Mlh1+/− mouse. “M” indicate those Mlh1+/− jejunum samples where Mlh1 
promoter methylation was detected. “M” in grey font indicates faint methylation signal. 
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analyzed. Mlh1 promoter methylation was present in tissues originating 
from all three germ layers: ectoderm (brain), mesoderm (spleen), 
endoderm (jejunum), and thus it was likely established already during 
early embryonic development in these mice. Our study provides first- 
time evidence of constitutive, but inter-individually stochastic, Mlh1 
promoter methylation in a MMR mouse model. This is analogous to the 
soma-wide Mlh1 promoter methylation in suspected LS patients who 
carry germline MMR epimutations (primarily Mlh1 promoter methyl-
ation) [40–46]. Despite constitutive Mlh1 promoter methylation in 
suspected LS patients, malignancies primarily occur in highly prolifer-
ating tissues, namely the GI tract, endometrium and skin. Tumors in 
these patients are MMR-deficient and may or may not show LOH of the 
unmethylated allele [40]. We show in Mlh1 mice that despite Mlh1 
promoter methylation in multiple tissues, MLH1 protein depletion is 
only observed in intestine of these mice; no concomitant LOH was 
detected. This observation in the pre-neoplastic setting could explain 
incidence of cancers in suspected LS patients without LOH [40]. Most 
(72 %) but not all Mlh1+/− mice with constitutive Mlh1 promoter 
methylation showed intestine-specific MLH1 depletion, and thus Mlh1 
promoter methylation alone cannot account for the low MLH1 level in 
Mlh1 heterozygote jejuna. Likely, other (so far unidentified) underlying 
regulatory mechanisms impact MMR protein levels in the GI tract. It is 
worth noting that tissues from Mlh1− /− mice also showed consistent 
Mlh1 promoter methylation signal, indicating that the Mlh1 knock-out 
allele is also frequently methylated. Obviously, methylation of the 
promoter of a non-functional gene will not reduce protein level, since 
the protein is not expressed in the first place. In jejuna of young Mlh1 
heterozygotes, Mlh1 promoter methylation associated – albeit not 
perfectly – with MLH1 depletion, while no such clear association was 
observed in the older cohort. Perhaps in older Mlh1 heterozygotes, more 
of the MSP signal originates from the knock-out allele and in such cells, 
there would be no impact on MLH1 protein levels. In individual cells 
methylation is not static, but instead a dynamic process where the 
promoter undergoes de- and re-methylation. We speculate that over 
time (i.e. in older Mlh1+/− mice), the knock-out Mlh1 allele may be more 
likely than the wildtype allele to exist in the methylated state, because 
de-methylation of a non-functional allele may be less efficient. However, 
given its strong association with elevated MSI and depleted MLH1 levels 
in jejunum of young mice, constitutive Mlh1 promoter methylation has 
excellent potential as a reporter for early, pre-neoplastic genome 
instability in tissues vulnerable for MMR-associated tumorigenesis. The 
fact that Mlh1 promoter methylation can be scored by MSP on DNA 
extracted from peripheral blood facilitates its use as a biomarker. 
In humans, LS individuals are most susceptible to colorectal and 
endometrial cancer [40–45]. In Mlh1+/− mice, though overall tumor 
incidence is low, both GI and non-GI tract tumors, namely lymphoma, 
cervical squamous cell carcinoma and lung bronchio-alveolar carci-
noma, are found [20]. In both humans and mice, tumor spectra associ-
ated with defective MMR comprise of proliferative tissues or cell types. 
Here we show that pre-neoplastic MSI and decreased MLH1 levels spe-
cifically impact the intestine, a highly proliferating tissue, in Mlh1+/−
mice. Similar, subtle and early molecular events may also prevail in 
other tissues/cell types with high turnover rate (such as endometrium) 
making them vulnerable to MMR-dependent tumorigenesis. 
Although MSI reports on global MMR defects, MSI per se does not 
necessarily lead to tumorigenesis [20]. If MSI occurs in coding micro-
satellites, the gene function may be disrupted, which in turn can lead to 
malignancy and tumorigenesis. Such genes include tumor suppressors 
and oncogenes which are involved in different regulatory pathways, 
including cell proliferation, cell cycle, apoptosis, and DNA repair [47, 
48]. We did not observe any tumors in Mlh1+/− jejunum, although this 
observation was limited to mice that were sacrificed to harvest tissues 
(we did not examine post-mortem the 30 % Mlh1+/− mice which died in 
our care; Supplementary Fig. 13). It is likely that many, if not all, 
Mlh1+/− mice for which the cause of death was not determined, suc-
cumbed to MMR-associated tumors. The 4-month-old outlier Mlh1+/−
mouse, whose jejunum had a deletion rate similar to age-matched 
Mlh1− /− mice, would presumably have had a higher chance of accu-
mulating mutations in MSI-target genes that, over time, may have trig-
gered tumorigenesis in the GI tract of this animal. 
This is the first systematic study to establish the relationship between 
MLH1 levels and MSI in a range of normal murine tissues. MSI in non- 
neoplastic mucosa [16] and crypt cells [49] has been reported in LS 
patient samples that likely were MMR-deficient. We demonstrate here 
that MSI is detectable – albeit at quite a low level – in Mlh1+/− jejunum 
that still retains close-to-expected (50 % of wildtype) MLH1 protein 
level, implicating MMR haploinsufficiency in normal, tumor-free 
Mlh1+/− intestine. High MSI only ensued upon substantial reduction 
of MMR protein levels. Thus, MMR function appears to rely on a critical 
threshold level of MMR proteins, in line with in vitro studies [17,18]. 
Importantly, MLH1 depletion was tissue-specific: it was observed only in 
jejunum and not in other tissues assayed. 
Given that the maintenance of genome stability is essential for all 
cells, it has been puzzling why germline mutations of key DNA repair 
pathways (mismatch repair, homologous recombination) give rise to 
cancer only in certain tissues. The tissue-specific haploinsufficiency of 
Mlh1 now provides a clue to why the GI tract is vulnerable to MMR- 
associated cancers. Analogously, heterozygosity of homologous recom-
bination genes, namely BRCA1 and PALB2, also confers subtle genome 
instability phenotypes that are detectable in pre-malignant cells of 
mutation carriers, provided that sufficiently sensitive assays are used 
[50,51]. We propose that tissue-specific decrease in protein levels is an 
important factor in determining which organs are cancer-prone in het-
erozygous DNA repair mutation carriers. 
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